Metformin restores the correlation between serum-oxidized LDL and leptin levels in type 2 diabetic patients

Redox Report

Volumn 16, Issue 5, 2011, Pages 193-200

  Nakhjavani, Manouchehr ^a   Morteza, Afsaneh ^a   Asgarani, Firuzeh ^a   Mokhtari, Abnoos ^a   Esteghamati, Alireza ^a   Khalilzadeh, Omid ^a   Rahbari, Ghazaleh ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Diabetes mellitus; Insulin resistance; Leptin; Metformin; Oxidative stress; Oxidized LDL; Type 2

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; LEPTIN; METFORMIN; OXIDIZED LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; AGE; ARTICLE; BODY MASS; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DIABETIC PATIENT; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HOMEOSTATIC MODEL ASSESSMENT OF INSULIN RESISTANCE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LEPTIN; LIPOPROTEINS, LDL; MALE; METFORMIN; MIDDLE AGED; OXIDATIVE STRESS;

EID: 80053922435     PISSN: 13510002     EISSN: 17432928     Source Type: Journal    
DOI: 10.1179/1351000211Y.0000000008     Document Type: Article

References (61)

1. Sies H. Oxidative stress: from basic research to clinical application. Am J Med 1991;91:31S-8S.
2. Parthasarathy S, Raghavamenon A, Garelnabi MO, Santanam N. Oxidized low-density lipoprotein. Methods Mol Biol 2010;610: 403-17.
3. Schwartz CJ, Valente AJ, Sprague EA, Kelley JL, Cayatte AJ, Rozek MM. Pathogenesis of the atherosclerotic lesion. Implications for diabetes mellitus. Diabetes Care 1992;15: 1156-67.
4. Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci USA 1987;84:2995-8.
5. Holvoet P, Lee DH, Steffes M, Gross M, Jacobs Jr DR. Association between circulating oxidized low-density lipoprotein and incidence of the metabolic syndrome. Jama 2008;299: 2287-93.
6. Nakhjavani M, Esteghamati A, Asgarani F, Khalilzadeh O, Nikzamir A, Safari R. Association of oxidized low-density lipoprotein and transforming growth factor-beta in type 2 diabetic patients: a cross-sectional study. Transl Res 2009;153:86-90. Epub 2008 Dec 9.
7. Dardeno TA, Chou SH, Moon HS, Chamberland JP, Fiorenza CG, Mantzoros CS. Leptin in human physiology and therapeutics. Front Neuroendocrinol 2010;31:377-93. Epub 2010 Jun 17.
8. Lam QL, Lu L. Role of leptin in immunity. Cell Mol Immunol 2007;4:1-13.
9. Beltowski J, Wojcicka G, Jamroz A. Leptin decreases plasma paraoxonase 1 (PON1) activity and induces oxidative stress: the possible novel mechanism for proatherogenic effect of chronic hyperleptinemia. Atherosclerosis 2003;170:21-9.
10. Kaur S, Zilmer K, Leping V, Zilmer M. The levels of adiponectin and leptin and their relation to other markers of cardiovascular risk in patients with psoriasis. J Eur Acad Dermatol Venereol 2011;1111:1468-3083.
11. Konstantinidis D, Paletas K, Koliakos G, Kaloyianni M. Signaling components involved in leptin-induced amplification of the atherosclerosis-related properties of human monocytes. J Vasc Res 2009;46:199-208. Epub 2008 Oct 9.
12. Porreca E, Di Febbo C, Moretta V, Angelini A, Guglielmi MD, Di Nisio M, et al. Circulating leptin is associated with oxidized LDL in postmenopausal women. Atherosclerosis 2004;175: 139-43.
13. Njajou OT, Kanaya AM, Holvoet P, Connelly S, Strotmeyer ES, Harris TB, et al. Association between oxidized LDL, obesity and type 2 diabetes in a population-based cohort, the Health, Aging and Body Composition Study. Diabetes Metab Res Rev 2009;25:733-9.
14. Chakraborty A, Chowdhury S, Bhattacharyya M. Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients. Diabetes Res Clin Pract 2011;93:56-62.
15. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2009;32(Suppl 1):S62-7.
16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
17. Stofkova A. Leptin and adiponectin: from energy and metabolic dysbalance to inflammation and autoimmunity. Endocr Regul 2009;43:157-68.
18. Fernandez-Riejos P, Najib S, Santos-Alvarez J, Martin-Romero C, Perez-Perez A, Gonzalez-Yanes C, et al. Role of leptin in the activation of immune cells. Mediators Inflamm 2010;23. DOI: 10.1155/2010/568343.
19. Cheung CC, Clifton DK, Steiner RA. Proopiomelanocortin neurons are direct targets for leptin in the hypothalamus. Endocrinology 1997;138:4489-92.
20. Long YC, Zierath JR. AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest 2006;116:1776-83.
21. Sarigianni M, Bekiari E, Tsapas A, Kaloyianni M, Koliakos G, Paletas K. Effect of leptin and insulin resistance on properties of human monocytes in lean and obese healthy participants. Angiology 2010;61:768-74. Epub 2010 May 12.
22. Stringer DM, Sellers EA, Burr LL, Taylor CG. Altered plasma adipokines and markers of oxidative stress suggest increased risk of cardiovascular disease in first Nation youth with obesity or type 2 diabetes mellitus. Pediatr Diabetes 2009;10:269-77. Epub 2008 Oct 19.
23. Kassi E, Dalamaga M, Hroussalas G, Kazanis K, Merantzi G, Zachari A, et al. Adipocyte factors, high-sensitive C-reactive protein levels and lipoxidative stress products in overweight postmenopausal women with normal and impaired OGTT. Maturitas 2010;67:72-7. Epub 2010 Jun 8.
24. Demirel F, Bideci A, Cinaz P, Camurdan MO, Biberoglu G, Yesilkaya E, et al. Serum leptin, oxidized low density lipoprotein and plasma asymmetric dimethylarginine levels and their relationship with dyslipidaemia in adolescent girls with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2007;67:129-34. Epub 2007 Apr 25.
25. Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 1998; 394:897-901.
26. Pamuk GE, Demir M, Harmandar F, Yesil Y, Turgut B, Vural O. Leptin and resistin levels in serum of patients with hematologic malignancies: correlation with clinical characteristics. Exp Oncol 2006;28:241-4.
27. Mancuso P, Gottschalk A, Phare SM, Peters-Golden M, Lukacs NW, Huffnagle GB. Leptin-deficient mice exhibit impaired host defense in gram-negative pneumonia. J Immunol 2002;168: 4018-24.
28. Gruver AL, Sempowski GD. Cytokines, leptin, and stressinduced thymic atrophy. J Leukoc Biol 2008;84:915-23. Epub 2008 May 21.
29. Papaevangelou V, Papassotiriou I, Vounatsou M, Chrousos G, Theodoridou M. Changes in leptin serum levels in HIV-infected children receiving highly active antiretroviral therapy. Scand J Clin Lab Invest 2007;67:291-6.
30. Paz-Filho GJ, Delibasi T, Erol HK, Wong ML, Licinio J. Cellular immunity before and after leptin replacement therapy. J Pediatr Endocrinol Metab 2009;22:1069-74.
31. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995;269:540-3.
32. Sainz N, Rodriguez A, Catalan V, Becerril S, Ramirez B, Gomez-Ambrosi J, et al. Leptin administration downregulates the increased expression levels of genes related to oxidative stress and inflammation in the skeletal muscle of ob/ob mice. Mediators Inflamm 2010;30. DOI: 10.1155/2010/784343.
33. Vernooy JH, Bracke KR, Drummen NE, Pauwels NS, Zabeau L, van Suylen RJ, et al. Leptin modulates innate and adaptive immune cell recruitment after cigarette smoke exposure in mice. J Immunol 2010;184:7169-77. Epub 2010 May 19.
34. Clement K, Lahlou N, Ruiz J, Hager J, Bougneres P, Basdevant A, et al. Association of poorly controlled diabetes with low serum leptin in morbid obesity. Int J Obes Relat Metab Disord 1997;21:556-61.
35. Passaro A, Calzoni F, Zamboni PF, Manservigi D, Alberti L, Dalla Nora E, et al. Role of diabetes in influencing leptin concentration in elderly overweight patients. Eur J Endocrinol 2001;145:173-9.
36. Marita AR, Sarkar JA, Rane S. Type 2 diabetes in non-obese Indian subjects is associated with reduced leptin levels: study from Mumbai, Western India. Mol Cell Biochem 2005;275: 143-51.
37. Sivitz WI, Wayson SM, Bayless ML, Larson LF, Sinkey C, Bar RS, et al. Leptin and body fat in type 2 diabetes and monodrug therapy. J Clin Endocrinol Metab 2003;88:1543-53.
38. Scholze A, Rattensperger D, Zidek W, Tepel M. Low serum leptin predicts mortality in patients with chronic kidney disease stage 5. Obesity (Silver Spring) 2007;15:1617-22.
39. Don BR, Rosales LM, Levine NW, Mitch W, Kaysen GA. Leptin is a negative acute phase protein in chronic hemodialysis patients. Kidney Int 2001;59:1114-20.
40. Ozata M, Gungor D, Turan M, Ozisik G, Bingol N, Ozgurtas T, et al. Improved glycemic control increases fasting plasma acylation-stimulating protein and decreases leptin concentrations in type II diabetic subjects. J Clin Endocrinol Metab 2001;86: 3659-64.
41. Nar A, Gedik O. The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Acta Diabetol 2009;46:113-8. Epub 2008 Oct 7.
42. Kanaley JA, Fenicchia LM, Miller CS, Ploutz-Synder LL, Weinstock RS, Carhart R, et al. Resting leptin responses to acute and chronic resistance training in type 2 diabetic men and women. Int J Obes Relat Metab Disord 2001;25:1474-80.
43. Wasim H, Al-Daghri NM, Chetty R, McTernan PG, Barnett AH, Kumar S. Relationship of serum adiponectin and resistin to glucose intolerance and fat topography in South-Asians. Cardiovasc Diabetol 2006;5:10.
44. Morin-Papunen LC, Koivunen RM, Tomas C, Ruokonen A, Martikainen HK. Decreased serum leptin concentrations during metformin therapy in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998;83:2566-8.
45. Cusi K, Consoli A, DeFronzo RA. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996;81: 4059-67.
46. Wright Jr E, Scism-Bacon JL, Glass LC. Oxidative stress in type 2 diabetes: the role of fasting and postprandial glycaemia. Int J Clin Pract 2006;60:308-14.
47. Erguder IB, Karagenc N, Karaca L. Reduced antioxidant potential & sensitivity to oxidation in plasma low density lipoprotein fraction in type 2 diabetes mellitus patients. Indian J Med Res 2006;124:207-10.
48. Rifici VA, Schneider SH, Khachadurian AK. Stimulation of lowdensity lipoprotein oxidation by insulin and insulin like growth factor I. Atherosclerosis 1994;107:99-108.
49. Carantoni M, Abbasi F, Warmerdam F, Klebanov M, Wang PW, Chen YD, et al. Relationship between insulin resistance and partially oxidized LDL particles in healthy, nondiabetic volunteers. Arterioscler Thromb Vasc Biol 1998;18:762-7.
50. Kanigur-Sultuybek G, Ozdas SB, Curgunlu A, Tezcan V, Onaran I. Does metformin prevent short-term oxidant-induced dna damage? In vitro study on lymphocytes from aged subjects. J Basic Clin Physiol Pharmacol 2007;18:129-40.
51. Correia S, Carvalho C, Santos MS, Proenca T, Nunes E, Duarte AI, et al. Metformin protects the brain against the oxidative imbalance promoted by type 2 diabetes. Med Chem 2008;4: 358-64.
52. Matsumoto T, Noguchi E, Ishida K, Kobayashi T, Yamada N, Kamata K. Metformin normalizes endothelial function by suppressing vasoconstrictor prostanoids in mesenteric arteries from OLETF rats, a model of type 2 diabetes. Am J Physiol Heart Circ Physiol 2008;295:H1165-76. Epub 2008 Jul 18.
53. Xie W, Zhang SD, Ou XP, Yang TL. Protective effects of metformin on low-density lipoprotein-induced endothelial dysfunction in rats. Nan Fang Yi Ke Da Xue Xue Bao 2009;29: 890-3.
54. Formoso G, De Filippis EA, Michetti N, Di Fulvio P, Pandolfi A, Bucciarelli T, et al. Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects. Diabetes Metab Res Rev 2008;24:231-7.
55. Rabbani N, Chittari MV, Bodmer CW, Zehnder D, Ceriello A, Thornalley PJ. Increased glycation and oxidative damage to apolipoprotein B100 of LDL cholesterol in patients with type 2 diabetes and effect of metformin. Diabetes 2010;59:1038-45.
56. Iida KT, Kawakami Y, Suzuki M, Shimano H, Toyoshima H, Sone H, et al. Effect of thiazolidinediones and metformin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats. Am J Physiol Endocrinol Metab 2003;284:E1125-30.
57. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-74.
58. Gilmore TD. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 2006;25:6680-4.
59. Perkins ND. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 2007;8:49-62.
60. Arai M, Uchiba M, Komura H, Mizuochi Y, Harada N, Okajima K. Metformin, an antidiabetic agent, suppresses the production of tumor necrosis factor and tissue factor by inhibiting early growth response factor-1 expression in human monocytes in vitro. J Pharmacol Exp Ther 2010;334:206-13.
61. Vasconcelos EM, Degasperi GR, de Oliveira HC, Vercesi AE, de Faria EC, Castilho LN. Reactive oxygen species generation in peripheral blood monocytes and oxidized LDL are increased in hyperlipidemic patients. Clin Biochem 2009;42:1222-7.